Literature DB >> 16517073

Detection of compound heterozygous deletions in the parkin gene of fibroblasts in patients with autosomal recessive hereditary parkinsonism (PARK2).

Kazuhiro Nakaso1, Yoshiki Adachi, Kenichi Yasui, Kenji Sakuma, Kenji Nakashima.   

Abstract

Mutations in the parkin gene are a common cause of autosomal recessive, juvenile or early onset parkinsonism (PARK2). In this report, we use RT-PCR to detect compound heterozygous deletions of the parkin gene in fibroblasts from two cases of middle age-onset familial parkinsonism with lower extremities-dominant resting tremor and mild cogwheel rigidity. Although exonic amplification of the parkin gene showed a deletional mutation of exon 3-4, their family histories suggested that the deletional mutations were a compound heterozygous abnormality of discrete origin. Immunoblotting demonstrated that abundant Parkin protein was expressed in fibroblasts, but little expression was detected in lymphocytes. RT-PCR using RNA isolated from the patients' fibroblasts indicated a parkin mutation in this family that consisted of compound heterozygous deletions (del exon3-4/del exon3-5). These results suggest that RT-PCR using the patients' fibroblasts may be helpful for the detection of compound heterozygous abnormalities in the parkin gene.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16517073     DOI: 10.1016/j.neulet.2006.02.035

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  5 in total

1.  Parkin protects dopaminergic neurons against microtubule-depolymerizing toxins by attenuating microtubule-associated protein kinase activation.

Authors:  Yong Ren; Houbo Jiang; Fang Yang; Kazuhiro Nakaso; Jian Feng
Journal:  J Biol Chem       Date:  2008-12-11       Impact factor: 5.157

2.  Breakpoint mapping of 13 large parkin deletions/duplications reveals an exon 4 deletion and an exon 7 duplication as founder mutations.

Authors:  Peter Elfferich; Marja C Verleun-Mooijman; J Anneke Maat-Kievit; Bart P C van de Warrenburg; Wilson F Abdo; Sylvia A Eshuis; Klaus L Leenders; Ad Hovestadt; Jan C M Zijlmans; Jan-Pieter M Stroy; John C van Swieten; Agnita J W Boon; Klaartje van Engelen; Corien C Verschuuren-Bemelmans; Saskia A J Lesnik-Oberstein; Cristina Tassorelli; Leonardo Lopiano; Vincenzo Bonifati; Dennis Dooijes; Rick van Minkelen
Journal:  Neurogenetics       Date:  2011-10-13       Impact factor: 2.660

3.  Parkinson's Disease in Saudi Patients: A Genetic Study.

Authors:  Bashayer R Al-Mubarak; Saeed A Bohlega; Thamer S Alkhairallah; Amna I Magrashi; Maha I AlTurki; Dania S Khalil; Basma S AlAbdulaziz; Hussam Abou Al-Shaar; Abeer E Mustafa; Eman A Alyemni; Bashayer A Alsaffar; Asma I Tahir; Nada A Al Tassan
Journal:  PLoS One       Date:  2015-08-14       Impact factor: 3.240

4.  Genomic instability in the PARK2 locus is associated with Parkinson's disease.

Authors:  Wojciech Ambroziak; Dariusz Koziorowski; Kinga Duszyc; Paulina Górka-Skoczylas; Anna Potulska-Chromik; Jarosław Sławek; Dorota Hoffman-Zacharska
Journal:  J Appl Genet       Date:  2015-04-02       Impact factor: 3.240

5.  Mutations in PRKN and SNCA Genes Important for the Progress of Parkinson's Disease.

Authors:  Anna Oczkowska; Wojciech Kozubski; Margarita Lianeri; Jolanta Dorszewska
Journal:  Curr Genomics       Date:  2013-12       Impact factor: 2.236

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.